\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesYear after year, the European Space Agency - ESA creates new technologies and applications, typically filing 10 new patent applications per year.
As a result, ESA has built a portfolio of around 550 patents and patent applications to date.
Now, through a permanent open call, companies and startups from around the world can submit their ideas on how they would mature these patents, paving the way for improved commercialisation of ESA's innovations.
"The main objective of this funding call is to establish collaboration with companies, making sure that ESA's ideas are never left in a drawer," says Mercedes Sánchez Álvarez, Technology Transfer Engineer at ESA.
If companies or startups have an idea for the technical and commercial maturation of ESA inventions, they can now share this idea through OSIP. ESA is accepting applications on a rolling basis and is available to fund the maturation of these ideas with a budget of up to 175k €. An updated list of patents that companies and startups can work on can be found in the open call under "Commercial and technical maturation of ESA's inventions".
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
